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ABSTRACT 
Objective: Antibiotics save millions of lives from infectious diseases worldwide. Failing treatment, serious adverse effects, and antimicrobial 
resistance are constantly reported mainly from developing nations due to lack of quality of antibiotics medicines. In India quality of medicines 
remains a major regulatory challenge and patients concern. Thus, a pilot study to explore the quality of generic amoxicillin products and associated 
price along with their burden on patients was evaluated. 
Methods: 46 amoxicillin trihydrate generic products with the label claim of 250 mg amoxicillin were procured from open market of Northern India 
without prescription. Identification and quantitative evaluations of these generic products were estimated using Indian Pharmacopoeia (IP) 2010 
recommended High-Performance Liquid Chromatography (HPLC) method. And assay value was compared with the maximum retail price per unit 
dosage. Affordability was estimated in general for the population who daily live on less than Indian rupees Rs. 144 and `88.6. 
Results: Out of 46 products, 28.26% were found to be out of IP specification, including 13.04% products which were of substandard quality. 
Fishers’ exact test with p-value 0.87 showed products quality gaps were irrespective of their price. Ceiling price of Rs. 3.04 per unit dosage pose a 
high burden on the patients who are on amoxicillin treatment.  
Conclusion: Situation demands the evidence of safety before approval and thereafter too. However, the situation may become worst if the price and 
quality could not be controlled. Thus Indian drug regulatory bodies need to be entreated to counter these critical issues. 
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INTRODUCTION 
“The dose makes the poison” as stipulated by Paracelsus. 
Consequently, the presence of active ingredient and its compliance 
to the pharmacopeia specifications considered as the most obvious 
paradigm for certifying the quality of drugs formulations [1]. From 
the majority of the developing countries; there are several reports of 
failing treatments, development of antimicrobial resistance and 
serious adverse drug reactions including death [2, 3]. In all 
probability, this is because of meager medications like spurious/ 
falsely-labeled/falsified/counterfeit (SFFC) medicines [2]. According 
to World Health Organization, “SFFC medicines include products 
with the correct ingredients or with the wrong ingredients, without 
active ingredients, with insufficient or too much active ingredient, or 
with fake packaging” [4]. Broadly poor quality medicines are divided 
into two categories viz. substandard and counterfeit [5]. From India, 
12-25% of supplied medicines globally may be contaminated, 
substandard and counterfeit [6]. On one side the number of poor 
quality medicine decreasing year by year [7] and on another side 
without scientific evidence Indian media consider 30-40% 
availability of the poor quality drug in domestic market [8]. When a 
product is manufactured it is being utilized by the patients; and 
availability of good quality medicines strengthen the chances of 
better treatment for the individual patient which advances 
improved results for general well being by and large [9]. In 
developing countries this poor quality situation stresses the patients 
without the known extent [5]. Likely in developing nations; 
medicines account for 25-70% of total heath care expenses [10]. 
Thereupon in the case of India where 58.01% and 21.2% of the 
population has daily living cost of less than Rs. 144 and Rs. 88.6 
respectively [11] then how could people afford the high price of 
medicines in addition to survival. Therefore Indian Government 
always emphasizes and promotes the affordable generic medicines 
for prescription and utilization [12]. The futile increase in the price 
of medicines is being wrangled on in the financial health care and 
public health domain, as it usually results in a reduced access of 
essential drugs [13]. Therefore to counteract the issue of spurious 
and substandard quality medicine in India there is an urgent 
demand for more research or routine analysis to document the 
magnitude of the problem. 
Antibiotics are the life-saving medicines [14], thus, an ideal antibiotic 
therapy is a prerequisite to treat the systemic spread of the infection 
and to prevent their complications [15]. Prescribing antibiotics 
irrationally is a general trend in India [16]. However, antibiotic 
medicines are considered as the most poor quality class or counterfeit 
worldwide and observed as the major threat for patients especially 
children [17]. Penicillin antibiotics like amoxicillin is largely 
prescribed drugs [18] and it is used as broad spectrum antibiotics 
which is considered as susceptible to the β lactamase-negative strains 
and species like Streptococcus pneumonia, Streptococcus species (α-and 
β-hemolytic strains only) and Haemophilus influenza etc. [19]. In 
recent years no study has been done overall or for any individual drug 
to explore the situation leaving behind no clear documentation on the 
current extent of the problem. Hence, the purpose of this pilot study 
was to explore quality and affordability of amoxicillin products; and 
scope in creating awareness to public and attention to regulatory 
bodies to evaluate such products.  
MATERIALS AND METHODS 
Chemicals and reagents 
Amoxicillin, trihydrate reference standard, was directly purchased 
from Sigma-Aldrich. HPLC grade acetonitrile (Lichrosolv), potassium 
dihydrogen phosphate (LiChropur), potassium hydroxide GR grade 
were procured from Merck (India). The polytetrafluoroethylene 
(PTFE) filter of 0.45 µm and nylon filter of 0.20 µm pore size from 
Millipore system (Millipore Inc., USA) was used throughout the 
evaluation. 
Instrument 
A HPLC system (Waters, Milford, MA, USA) equipped with Alliance 
2695 separations module with photodiode array detector was used 
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in this study. A reverse phase octadecylsilane bonded C-18 (250 
mm×46 mm, 5 µm) column (Waters) was employed throughout the 
analysis. All samples for evaluation were weighed on high sensitive 
analytical balance TB-215D (Denver Instrument, Germany). 
Chromatograms were recorded and processed using Empower Pro 
Software (Waters). 
Generic product collection 
All amoxicillin generic products used in this study were purchased 
without prescription from the open market from different location 
of Northern India. In total 46 generic products were collected which 
comprise 43 different products of amoxicillin trihydrate (AMOX) 
capsules and two tablets having 250 mg dose. Among them, one 
capsule product was collected of two batches thus in total 46 
products were collected. 
Standard and sample preparation 
For the identification and quantitative evaluation of amoxicillin in 
the finished pharmaceutical product, HPLC being highly sensitive 
and pharmacopeial established method was preferred. Thus in 
accordance to Indian Pharmacopoeia (IP) [20], 0.02M monobasic 
potassium phosphate buffer was prepared as a solvent mixture and 
adjusted to pH 5.0±0.05 using 4.5% potassium hydroxide (w/v) and 
finally filtered through 0.20 µm membrane nylon filter and degassed 
in an ultrasonic bath. An isocratic mobile phase of acetonitrile and 
solvent mixture in 4:96 v/v was used with a flow rate of 1.5 ml/min. 
Each analytical run was carried for 10 min with 10 µl injection 
volume, and data was acquired at 230 nm and processed. The 
solvent mixture was used as diluent in the preparation of analytical 
sample solutions. AMOX working reference standard (RS) solution of 
1.2 mg/ml concentration was used as system suitability solution.  
Test samples were prepared by mixing 250 mg equivalent to 
amoxicillin form content of ten capsules or tablets in diluent to 
prepare 1.2 mg/ml concentration. Samples were sonicated for 10 
min and filtered using 0.45 µm PTFE. Each sample was prepared in 
triplicate and also injected in triplicate to ensure the precise assay 
result. Against the mean area of five injections of AMOX RS; assay of 
amoxicillin in the test sample was determined on percent label claim 
of the active pharmaceutical ingredient present in individual capsule 
or tablet. According to IP for ten capsules the assay requires to be 
within 89.5–110.6% of the label claim and for ten tablets assay 
requires to be within 89.4-110.8% of the label claim [21]. While 
according to the Central Drug Standard Control Organization 
(CDSCO) a product is said to be substandard quality only if assay 
found 5% below the IP limit [22]. 
RESULTS AND DISCUSSION 
Our aim was not to expose any particular product or defame any 
company. Hence, product identity is not revealed. However the 
challenges involved in the collection and evaluation of substandard 
drugs in the market cannot be neglected; as all products were 
procured from the open market without prescription. 
Due to listed in National List of Essential Medicines (NLEM) [23], its 
extensive production [24] and extensive utilization [25] AMOX was 
selected. The analytical techniques chosen need to be specific to every 
product; thus, amoxicillin capsule monograph was selected from IP 
2010. However, the presence of excipients and another evaluation test 
like impurity profiling can determine the complete quality of the 
product. 
In evaluating the generic product, it is necessary to face up the 
interaction of complex matrix of the product. Thus, an assumed 
placebo was prepared by blending microcrystalline cellulose, 
magnesium stearate, croscarmellose, sodium and colloidal silicon 
dioxide. And this placebo was spiked with the reference standard to 
confirm the interference. System suitability was demonstrated to be 
appropriate for routine analysis purpose, thus, AMOX RS peak was 
confirmed by theoretical plate count, tailing factor and maximum 
absorption at 230 nm wavelength. Peak purity was also checked 
with the higher purity threshold than purity angle. The observed 




Fig. 1: Full-scale typical chromatogram of amoxicillin trihydrate reference standard 
 
In order to compare the quality of AMOX capsules or tablets, we 
identified its presence and calculated the amoxicillin quantity with 
respect to label claim. Out of 46 products the percentage content of 13 
products were not matched with the label claim. As shown in table 1, 13 
products were failed to follow the IP specification. And among them, six 
products were failed according to the specified limit by CDSCO. Thus, 
28.26% products were out of IP specification, and 13.04% products 
were of substandard quality, high demand for antibiotics which are often 
prescribed in developing countries and is a very profitable market for 
the manufacturers who deliberately manufactured such products. 
India has to ensure the continuity of the generic competition in order 
to respect, protect and fulfill the right to health of its people [26]. Thus 
additionally, we raise quibble over the consideration of price to be one 
of the controlling parameters influencing the access of medicines in 
India. Under article 21 of the Indian constitution; the right to health 
includes availability and accessibility to affordable drugs. While 
substandard product such as Amox Rs.14 and out of pharmacopeia 
specification products like Amox-05, Amox-21, Amox-09 and Amox-41 
were available in the market at high prices, range between `5.43-6.50 
as shown in fig. 2. However, recently National Pharmaceutical Pricing 
Authority (NPPA) of India has revised the price of several essential 
medicines. Current revised ceiling price of amoxicillin 250 mg capsule 
is `3.04 [27]. For instance, in the treatment of helicobacter pylori 
infection, one gram orally two to three times a day administration [28] 
of AMOX capsule only; would cost 16.88-25.33% and 27.63-41.45% of 
total daily living cost of 58.01% and 21.25% Indian population 
respectively out of their daily living cost and this burden will continue 
for 14 d till completion of treatment. Other medicine in combination 
would cost extra. In the same way for mild pneumonia to adult 500 mg 
three times a day administration [28] of AMOX capsule only; would 
cost 12.66% and 20.58% to the 58.01% and 21.25% population 
respectively out of their daily living cost and this burden will continue 
from seven to ten days. It is an alarming state where people are 
suffering, and the burdens of health care cost are increasing 
continuously. And on above all when treatment fails; situation become 
grievous with no treatment benefits and high financial burden. In 
addition, such quality also has a big contribution in antimicrobial 
resistance and unfortunately for one decade there is no antibiotic in 
the pipeline of the invention. 
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Table 1: Amoxicillin trihydrate generic products assay and price 


























AMOX-01A 98.80 99.37 101.36 99.84 1.34 1.34 5.90 
AMOX-01B 99.69 101.30 100.82 100.60 0.83 0.83 2.90 
AMOX-02 90.49 89.58 89.21 89.76 0.66 0.74 4.80 
AMOX-03 95.75 93.59 93.26 94.20 1.35 1.43 5.07 
AMOX-04 92.55 93.56 94.05 93.39 0.76 0.81 3.50 
AMOX-05 85.54 86.66 86.22 86.14 0.56 0.65 5.75 
AMOX-06 85.66 85.32 85.30 85.43 0.20 0.23 3.25 
AMOX-07 89.06 90.39 89.47 89.64 0.68 0.76 2.90 
AMOX-08 95.72 95.00 94.63 95.12 0.55 0.58 3.96 
AMOX-09 88.95 90.11 89.17 89.41 0.62 0.69 5.50 
AMOX-10 100.22 100.53 100.71 100.49 0.25 0.25 3.00 
AMOX-11 89.86 91.48 90.96 90.77 0.83 0.91 3.60 
AMOX-12 90.57 91.31 91.30 91.06 0.42 0.46 3.40 
AMOX-13 93.05 89.72 90.98 91.25 1.68 1.84 1.50 
AMOX-14 81.92 83.72 83.47 83.04 0.98 1.18 6.50 
AMOX-15 22.41 22.40 22.17 22.33 0.14 0.63 4.50 
AMOX-16 92.23 92.34 92.10 92.22 0.12 0.13 2.90 
AMOX-17 97.89 99.18 99.08 98.72 0.72 0.73 4.70 
AMOX-18 99.08 99.65 99.79 99.51 0.38 0.38 3.90 
AMOX-19 90.12 91.48 90.53 90.71 0.70 0.77 3.80 
AMOX-20 100.21 99.88 101.08 100.39 0.62 0.62 4.70 
AMOX-21 87.08 89.12 88.77 88.32 1.09 1.23 5.50 
AMOX-22 89.13 90.83 90.58 90.18 0.92 1.02 4.10 
AMOX-23 94.52 95.89 95.16 95.19 0.69 0.72 4.10 
AMOX-24 93.52 94.27 94.39 94.06 0.47 0.50 5.75 
AMOX-25 90.47 90.72 91.20 90.80 0.37 0.41 3.20 
AMOX-26 95.39 95.62 96.15 95.72 0.39 0.41 5.25 
AMOX-27 96.14 96.00 95.86 96.00 0.14 0.15 1.40 
AMOX-28 91.23 91.98 90.00 91.07 1.00 1.10 5.63 
AMOX-29 91.09 91.52 91.22 91.28 0.22 0.24 6.50 
AMOX-30 83.21 84.46 83.71 83.79 0.63 0.75 3.95 
AMOX-31 91.88 91.01 91.94 91.61 0.52 0.57 3.60 
AMOX-32 92.24 93.67 93.64 93.18 0.82 0.88 3.83 
AMOX-33 86.89 86.60 86.76 86.75 0.15 0.17 3.25 
AMOX-34 91.52 92.92 92.82 92.42 0.78 0.84 4.07 
AMOX-35 83.26 85.36 84.09 84.24 1.06 1.26 3.50 
AMOX-36 89.77 90.23 90.44 90.15 0.34 0.38 6.20 
AMOX-37 87.26 88.99 88.87 88.37 0.97 1.10 5.00 
AMOX-38 91.20 89.28 90.39 90.29 0.96 1.06 3.40 
AMOX-39 27.94 27.61 27.54 27.70 0.21 0.76 3.20 
AMOX-40* 105.92 106.12 105.76 105.93 0.18 0.17 4.00 
AMOX-41* 86.95 84.85 85.55 85.78 1.07 1.25 5.43 
AMOX-42 90.75 93.28 91.82 91.95 1.27 1.38 5.87 
AMOX-43 79.95 81.31 81.24 80.83 0.77 0.95 2.90 
AMOX-44 90.87 91.80 91.46 91.38 0.47 0.51 2.50 
AMOX-45 98.80 98.45 98.55 98.60 0.18 0.18 3.97 
*Tablets, Total number of samples N=46 
 
Patient demand affordable and quality generic products like Amox-13 
and Amox-27, which are manufactured by the companies who may have 
no motive to more profit but are more patient-centric. Raising 
competition with expanding the drug production ultimately lowers the 
price, improve the access and verify public benefits. 
Fisher’s exact test with two-tailed p-value 0.87 showed no significant 
difference between assay and price of the evaluated products. Based 
on Indian pharmaceutical generic scope and affordability; Indian 
Government promotes the generic medicines and recommend to 
prescribe them by the medical practitioners; but the practitioners 
must be aware of the sources, quality and all possible benefits and risk 
of the prescribed medication so as to educate the patients. Moreover, 
pharmacist’s involvement in switching the branded medicines to 
generic medicines may be a good intention only if pharmacists know 
the quality of medicines besides the trade brokerage. 
Another concern is selling the ‘Schedule H’ drug without 
prescription. As products were purchased directly from the retailer 
and wholesalers, and they didn’t ask for any prescription or the 
buyer identity. Maybe they consider medicines as a commodity. 
Thus, in short Drug and Cosmetic Act 1940 and Rules 1945 are 
improperly followed. Therefore good pharmacy practice guidelines 
[29] has to be followed for the safety of patients. Inversely due to 
patient’s lack of knowledge, unawareness of adverse effects and 
seller ignorance during trade may increase morbidity and mortality.  
It can be concluded that several products available in the market are 
of substandard quality. The high extremity of this situation, as 
shown by the results is not significantly related to low cost only as 
show in table 2. Precisely there is no single step to restrain the issue 
of quality medicine, however; the interventions adopted by 
regulatory authorities must be more practicable and durable to 
uproot the cause of the problem. As a part of interventions, 
education and providing information to the public may enhance 
awareness. Other feasible strategies have been increasing the 
number of testing laboratories, and use a fast and efficient method 
like near infrared spectroscopy or capillary electrophoresis for 
monitoring the poor quality medicines trade. 
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Fig. 2: Maximum retail price versus assay plot showing generic amoxicillin products (N=46) quality 
 
Table 2: Price wise distribution of passed and failed AMOX products 
Maximum retail price per capsule/tablet Rs. No. of products failed No. of products passed 
1-2 - 2 
>2-3 1 5 
>3-4 6 11 
>4-5 2 5 
>5-6 4 6 
>6-7 1 2 
 
CONCLUSION 
When people in developing countries don’t have access to quality 
medicine at an affordable price, improving regulatory system should 
be the first challenge that has to take care off. As many substandard 
products are available in the market and ready to use by the patients 
for their treatment. These results would create awareness among 
the public and drug regulatory authorities about a brief extent of the 
problem. The patient can compromise with price but patients' health 
cannot be compromised with poor quality. Therefore, situation 
demands the evidence of safety before approval and thereafter too. 
Improved quality of antibiotics and inclusion of additional 
parameters for their effective supply and strategies may further 
eliminate the antibiotic resistance. Study determine the requirement 
for further investigation into how this substandard product are 
available in the market and explore other quality compromised 
medicines in order to protect the public health and promote the 
health system.  
CONFLICT OF INTERESTS 
The authors declare no conflict of interest 
REFERENCES  
1. Taylor RB, Shakoor O, Behrens RH, Everard M, Low AS, 
Wangboonskul J, et al. the Pharmacopoeial quality of drugs 
supplied by Nigerian pharmacies. Lancet 2001;357:1933–6. 
2. Heyman ML, Williams RL. Ensuring global access to quality 
medicines: the role of the US pharmacopeia. J Pharm Sci 
2011;100:1280–7. 
3. King DR, Kanavos P. Encouraging the use of generic medicines: 
implications for transition economies. Croat Med J 
2002;43:462–9. 
4. WHO. Medicines: spurious/ falsely-labelled/ falsified/ 
counterfeit (SFFC) medicines. World Health Organization; 
2012. Available from: http://www.who.int/ mediacentre/ 
factsheets/fs275/en/. [Last accessed 15 Jan 2015]. 
5. Newton PN, Green MD, Fernández FM. The impact of poor-
quality medicines in the ‘developing’ world. Trends Pharmacol 
Sci 2010;31:99–101. 
6. PSM. Counterfeit Drug Incident Encyclopedia. Partnership for 
Safe Medicines; 2013. Available from: http://www. 
safemedicines.org/counterfeit-drug-incident-
encyclopedia.html. [Last accessed on 12 Jan 2015]. 
7. Khan AN, Khar RK. Current scenario of spurious and 
substandard medicines in india: a systematic review. Indian J 
Pharm Sci 2015;77:2–7. 
8. PSM. Proposed methodology to conduct a study on the extent 
of spurious drugs in the supply chain of Indian market. India. 
2010 Available from: http://www.safemedicinesindia.in/ 
pdf/Methodology.pdf. 
9. Suleman S, Zeleke G, Deti H, Mekonnen Z, Dichateau L, Levecke 
B, et al. Quality of medicines commonly used in the treatment 
of soil-transmitted helminths and giardia in ethiopia: a 
nationwide survey. PLoS Neglected Trop Dis 2014;8:e3345. 
10. WHO. WHO Medicine Strategy: Countries at the core. Geneva; 
2007. Available from: http://apps.who.int/medicinedocs/ 
pdf/s5416e/s5416e.pdf. 
11. World Bank. Poverty Headcount Ratio India 2011. World Bank; 
2015. Available from: http://data.worldbank.org/ indicator/ 
SI.POV.2DAY/countries/IN?display=graph. [Last accessed on 
22 Oct 2015]. 
12. PIB. Bill on Mandatory Usage of Generic Names of Medicines. 
Press Information Bureau of India; 2013. Available from: 
http://pib.nic.in/newsite/PrintRelease.aspx?relid=93018. 
[Last accessed on 16 Dec 2014]. 
Khan et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 1, 386-390 
390 
13. The World Medicines Situation; 2004. Available from: 
http://apps.who.int/medicinedocs/pdf/s6160e/s6160e.pdf. 
[Last accessed on 16 Dec 2014]. 
14. NIH. Antibiotics. US. National Library of Medicine. Available 
from: https://www.nlm.nih.gov/medlineplus/antibiotics.html. 
[Last accessed 12 Feb 2015]. 
15. Bauters TGM, Nguyen BT, Buyle F, Schelstraete P, De Cock P, De 
Jaegar A, et al. Clinical pharmacy and pediatrics: Why focus on 
antibiotics? Pharm World Sci 2006;28:3–5. 
16. Kotwani A, Wattal C, Joshi PC, Holloway K. Irrational use of 
antibiotics and role of the pharmacist: an insight from a 
qualitative study in New Delhi, India. J Clin Pharm Ther 
2012;37:308–12. 
17. Delepierre A, Gayot A, Carpentier A. Update on counterfeit 
antibiotics worldwide; public health risks. Médecine Maladies 
Infect 2012;42:247–55. 
18. Rossignoli A, Clavenna A, Bonati M. Antibiotic prescription, and 
prevalence rate in the paediatric outpatient population: 
analysis of surveys published during 2000-2005. Eur J Clin 
Pharmacol 2007;63:1099–106. 
19. NIH. Amoxicillin Capsule. U. S. National Library of Medicine. 
Available from: http://dailymed.nlm.nih.gov/dailymed/ 
drugInfo.cfm?setid=649d285c-8fcb-48dd-aa5e-2f34128102f5. 
[Last accessed on 10 Jun 2015]. 
20. Indian Pharmacopoeia Commission. Amoxicillin Capsule. The 
Indian Pharmacopoiea Commision, Ghaziabad; 2010. p. 813–4. 
21. Indian Pharmacopoeia Commission. Indian Pharmacopoeia, 
Sixth. Ghaziabad: The Indian Pharmacopoeia Commission; 2010. 
22. CDSCO. Guidelines for taking action on samples of drug 
declared spurious or not of standard quality in the light of 
enhanced penalties under Drug and Cosmetic (Amendment): 
New Delhi; 2008. Available from: http://www.cdsco.nic.in/ 
write read data/DCC Guidelines on NSQ Drugs.pdf. [Last 
accessed on 20 Aug 2015]. 
23. Government of India. National list of essential medicines of India. 
New Delhi; 2011. Available from:  http:// pharmaceuticals. 
gov.in/nlem.pdf. [Last accessed on 20 Aug 2015]. 
24. NPPA. Production Details 2005-2008. The government of India. 
Available from: http://www.nppaindia.nic.in. [Last accessed on 
10 Oct 2014]. 
25. Kotwani A, Holloway K. Trends in antibiotic use among 
outpatients in New Delhi, India. BMC Infect Dis 2011;11:99. 
26. Grover A, Citro B. India: access to affordable drugs and the 
right to health. Lancet 2011;377:976–7. 
27. NPPA. Ceiling price of scheduled medicines fixed/revised under 
DPCO, 2013. MCF, Government of India; 2014. Available from: 
http://www.nppaindia.nic.in. [Last accessed on 10 Jan 2015]. 
28. Amoxicillin Dosage; 2015. Available from: http:// www. 
drugs.com/dosage/amoxicillin.html. [Last accessed on 14 Mar 
2015]. 
29. Indian Pharmaceutical Association. Good Pharmacy Practice 
Guidelines. Mumbai; 2002. Available from: http://www. 
ipapharma.org/html/GPP_Guidelines_IPA2002.pdf. [Last 
accessed on 20 Aug 2015].  
 
